Prinessa Chellan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prinessa Chellan has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Gregory Stuart Smith
Department of Chemistry, Faculty of Science, University of Cape Town, Rondebosch, 7701, South Africa
18 shared publications Kelly Chibale
Department of Chemistry, University of Cape Town, Private Bag, Rondebosch 7701, South Africa
9 shared publications- Peter J. Sadler
Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK
7 shared publications Peter J. Smith
7 shared publications- Tameryn Stringer
Department of Chemistry, University of Cape Town, Rondebosch, 7701, Cape Town, South Africa
6 shared publications Ajit Shokar
Department of Biological Sciences, University of the Pacific, Stockton, CA 95211, United States of America
5 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 44 (24) , 2829-2833
Multichiral Half-Sandwich Ru(II) and Os(II) Anticancer Complexes Containing a Glutathione Synthesis Inhibitor
Two novel half-sandwich organometallic complexes, [(p-cymene)M(XY)Cl], XY = L-BSO, M = RuII (Ru-LBSO), OsII (Os-LBSO), containing the amino acid L-buthionine sulfoximine (L-BSO), as well as their XY = glycine analogs (Ru-Gly and Os-Gly), have been synthesized, characterized and their solution chemistry investigated. L-BSO is an inhibitor of the enzyme γ-glutamyl cysteine synthetase and, hence, glutathione synthesis. The diastereomers of Ru-LBSO and Os-LBSO were also characterized by DFT calculations which suggested the higher stability of [SM,rS] and [SM,sS] compared to [RM,rS] and [RM,sS] configurations [chirality at M(II), chirality at sulfur of L-BSO]. Interestingly, glycine complexes are non-toxic toward both cancer and normal cells, whereas Os-LBSO was cytotoxic toward human IGROV-1 ovarian cancer cells, but not toward lung and cervical cancer cells. Os-LBSO, but not Ru-LBSO, demonstrated glutathione inhibition. These studies on Ru-LBSO and Os-LBSO complexes demonstrate the challenges of making progress toward the development for clinical use of organometallic complexes that contain multiple chiral centers. However, they offer exciting possibilities for discovery of novel drugs with new mechanisms of action.
- 11 December 2025
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 44 (24) , 2829-2833
Open AccessMultichiral Half-Sandwich Ru(II) and Os(II) Anticancer Complexes Containing a Glutathione Synthesis Inhibitor
Two novel half-sandwich organometallic complexes, [(p-cymene)M(XY)Cl], XY = L-BSO, M = RuII (Ru-LBSO), OsII (Os-LBSO), containing the amino acid L-buthionine sulfoximine (L-BSO), as well as their XY = glycine analogs (Ru-Gly and Os-Gly), have been synthesized, characterized and their solution chemistry investigated. L-BSO is an inhibitor of the enzyme γ-glutamyl cysteine synthetase and, hence, glutathione synthesis. The diastereomers of Ru-LBSO and Os-LBSO were also characterized by DFT calculations which suggested the higher stability of [SM,rS] and [SM,sS] compared to [RM,rS] and [RM,sS] configurations [chirality at M(II), chirality at sulfur of L-BSO]. Interestingly, glycine complexes are non-toxic toward both cancer and normal cells, whereas Os-LBSO was cytotoxic toward human IGROV-1 ovarian cancer cells, but not toward lung and cervical cancer cells. Os-LBSO, but not Ru-LBSO, demonstrated glutathione inhibition. These studies on Ru-LBSO and Os-LBSO complexes demonstrate the challenges of making progress toward the development for clinical use of organometallic complexes that contain multiple chiral centers. However, they offer exciting possibilities for discovery of novel drugs with new mechanisms of action.
- Open Access
- 7 August 2025
- Published by Elsevier in Journal of Organometallic Chemistry
- Vol. 1039
Organometallic conjugates of artesunate: synthesis and evaluation of anticancer potential
- 7 August 2025
- Published by Elsevier in Journal of Organometallic Chemistry
- Vol. 1039
Open AccessOrganometallic conjugates of artesunate: synthesis and evaluation of anticancer potential
- Open Access
- 10 September 2024
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 48 (37) , 16415-16428
Synthesis of ferrocenyl benzimidazole derivatives as novel anti-Toxoplasma gondii agents
New ferrocenyl-benzimidazole compounds with anti-Toxoplasma gondii activity were synthesized and characterized. The compounds had redox activity and led to the accumulation of reactive oxygen species within parasites.
- 10 September 2024
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 48 (37) , 16415-16428
Open AccessSynthesis of ferrocenyl benzimidazole derivatives as novel anti-Toxoplasma gondii agents
New ferrocenyl-benzimidazole compounds with anti-Toxoplasma gondii activity were synthesized and characterized. The compounds had redox activity and led to the accumulation of reactive oxygen species within parasites.
- Open Access
- 8 September 2023
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 52 (43) , 15786-15797
Investigation of new ferrocenyl-artesunate derivatives as antiparasitics
Ferrocene conjugated artesunate ( Ars ) derivatives with antiparasitic effects.
- 8 September 2023
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 52 (43) , 15786-15797
Open AccessInvestigation of new ferrocenyl-artesunate derivatives as antiparasitics
Ferrocene conjugated artesunate ( Ars ) derivatives with antiparasitic effects.
- 3 February 2023
- Published by Elsevier in Journal of Organometallic Chemistry
- Vol. 987-988
Investigation of bioorganometallic artemisinins as antiplasmodials
- 3 February 2023
- Published by Elsevier in Journal of Organometallic Chemistry
- Vol. 987-988
Investigation of bioorganometallic artemisinins as antiplasmodials
- 1 June 2021
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 219, 111408
Bioactive half-sandwich Rh and Ir bipyridyl complexes containing artemisinin
- 1 June 2021
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 219, 111408
Bioactive half-sandwich Rh and Ir bipyridyl complexes containing artemisinin
- 1 March 2021
- Published by Elsevier in Inorganica Chimica Acta
- Vol. 517
Synthesis and antimicrobial study of organoiridium amido-sulfadoxine complexes
- 1 March 2021
- Published by Elsevier in Inorganica Chimica Acta
- Vol. 517
Synthesis and antimicrobial study of organoiridium amido-sulfadoxine complexes
- Open Access
- 17 July 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (40)
Frontispiece: Enhancing the Activity of Drugs by Conjugation to Organometallic Fragments
- 17 July 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (40)
Open AccessFrontispiece: Enhancing the Activity of Drugs by Conjugation to Organometallic Fragments
- 27 May 2020
- Published by Royal Society of Chemistry (RSC)
- p. 230-260
CHAPTER 8. Metallodendrimers: Synthetic Strategies and Current Structural Trends
Metallodendrimers can be systematically classified according to the location of the metal centres within the dendritic framework. Dendrimers can be functionalized with various metals on the periphery through many suitable end groups, in their core, along their branches, and in the cavities that exist within their framework. These different structures possess unique architectures and topologies with associated specific functions, with potential in a myriad of fields. This chapter summarizes the recent developments in the synthesis and functionalization of dendrimers with various metal centres.
- 27 May 2020
- Published by Royal Society of Chemistry (RSC)
- p. 230-260
CHAPTER 8. Metallodendrimers: Synthetic Strategies and Current Structural Trends
Metallodendrimers can be systematically classified according to the location of the metal centres within the dendritic framework. Dendrimers can be functionalized with various metals on the periphery through many suitable end groups, in their core, along their branches, and in the cavities that exist within their framework. These different structures possess unique architectures and topologies with associated specific functions, with potential in a myriad of fields. This chapter summarizes the recent developments in the synthesis and functionalization of dendrimers with various metal centres.
- Open Access
- 26 May 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (40) , 8676-8688
Enhancing the Activity of Drugs by Conjugation to Organometallic Fragments
Resistance to chemotherapy is a current clinical problem, especially in the treatment of microbial infections and cancer. One strategy to overcome this is to make new derivatives of existing drugs by conjugation to organometallic fragments, either by an appropriate linker, or by direct coordination of the drug to a metal. We illustrate this with examples of conjugated organometallic metallocene sandwich and half‐sandwich complexes, RuII and OsII arene, and RhIII and IrIII cyclopentadienyl half‐sandwich complexes. Ferrocene conjugates are particularly promising. The ferrocene–chloroquine conjugate ferroquine is in clinical trials for malaria treatment, and a ferrocene‐tamoxifen derivative (a ferrocifen) seems likely to enter anticancer trails soon. Several other examples illustrate that organometallic conjugation can restore the activity of drugs to which resistance has developed.
- 26 May 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (40) , 8676-8688
Open AccessEnhancing the Activity of Drugs by Conjugation to Organometallic Fragments
Resistance to chemotherapy is a current clinical problem, especially in the treatment of microbial infections and cancer. One strategy to overcome this is to make new derivatives of existing drugs by conjugation to organometallic fragments, either by an appropriate linker, or by direct coordination of the drug to a metal. We illustrate this with examples of conjugated organometallic metallocene sandwich and half‐sandwich complexes, RuII and OsII arene, and RhIII and IrIII cyclopentadienyl half‐sandwich complexes. Ferrocene conjugates are particularly promising. The ferrocene–chloroquine conjugate ferroquine is in clinical trials for malaria treatment, and a ferrocene‐tamoxifen derivative (a ferrocifen) seems likely to enter anticancer trails soon. Several other examples illustrate that organometallic conjugation can restore the activity of drugs to which resistance has developed.